Healthcare stocks are generally more resilient in a challenging macro backdrop compared to stocks in other sectors. This is because the need for medicines and medical treatments i ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

We expect disappointing results in the first quarter will be balanced by higher-than-anticipated growth in the second half.